These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 23181570)

  • 1. Deubiquitinating enzymes as therapeutic targets in cancer.
    Lim KH; Baek KH
    Curr Pharm Des; 2013; 19(22):4039-52. PubMed ID: 23181570
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The therapeutic potential of deubiquitinating enzyme inhibitors.
    Colland F
    Biochem Soc Trans; 2010 Feb; 38(Pt 1):137-43. PubMed ID: 20074048
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ubiquitin-based anticancer therapy: carpet bombing with proteasome inhibitors vs surgical strikes with E1, E2, E3, or DUB inhibitors.
    Mattern MR; Wu J; Nicholson B
    Biochim Biophys Acta; 2012 Nov; 1823(11):2014-21. PubMed ID: 22610084
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ubiquitin-proteasome system (UPS) as a target for anticancer treatment.
    Park J; Cho J; Song EJ
    Arch Pharm Res; 2020 Nov; 43(11):1144-1161. PubMed ID: 33165832
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Deubiquitinases (DUBs) and DUB inhibitors: a patent review.
    Farshi P; Deshmukh RR; Nwankwo JO; Arkwright RT; Cvek B; Liu J; Dou QP
    Expert Opin Ther Pat; 2015; 25(10):1191-1208. PubMed ID: 26077642
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The ubiquitin-proteasome system (UPS) and the mechanism of action of bortezomib.
    Cvek B; Dvorak Z
    Curr Pharm Des; 2011; 17(15):1483-99. PubMed ID: 21504411
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Deubiquitinase inhibition as a cancer therapeutic strategy.
    D'Arcy P; Wang X; Linder S
    Pharmacol Ther; 2015 Mar; 147():32-54. PubMed ID: 25444757
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting Deubiquitinases in Cancer.
    Bednash JS; Mallampalli RK
    Methods Mol Biol; 2018; 1731():295-305. PubMed ID: 29318562
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Emerging potential of therapeutic targeting of ubiquitin-specific proteases in the treatment of cancer.
    Pal A; Young MA; Donato NJ
    Cancer Res; 2014 Sep; 74(18):4955-66. PubMed ID: 25172841
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Proteasome deubiquitinases as novel targets for cancer therapy.
    D'Arcy P; Linder S
    Int J Biochem Cell Biol; 2012 Nov; 44(11):1729-38. PubMed ID: 22819849
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ubiquitin-proteasome system as a target for anticancer treatment-an update.
    Kim YJ; Lee Y; Shin H; Hwang S; Park J; Song EJ
    Arch Pharm Res; 2023 Jul; 46(7):573-597. PubMed ID: 37541992
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting Deubiquitinating Enzymes and Autophagy in Cancer.
    Mooneyham A; Bazzaro M
    Methods Mol Biol; 2017; 1513():49-59. PubMed ID: 27807830
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting the ubiquitin-proteasome pathway with inorganic compounds to fight cancer: a challenge for the future.
    Dalla Via L; Nardon C; Fregona D
    Future Med Chem; 2012 Mar; 4(4):525-43. PubMed ID: 22416778
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting the ubiquitin proteasome system: beyond proteasome inhibition.
    Xolalpa W; Perez-Galan P; Rodríguez MS; Roué G
    Curr Pharm Des; 2013; 19(22):4053-93. PubMed ID: 23181575
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Deubiquitinating enzyme inhibitors and their potential in cancer therapy.
    Crosas B
    Curr Cancer Drug Targets; 2014; 14(6):506-16. PubMed ID: 25088039
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The DUB Club: Deubiquitinating Enzymes and Neurodevelopmental Disorders.
    Jolly LA; Kumar R; Penzes P; Piper M; Gecz J
    Biol Psychiatry; 2022 Oct; 92(8):614-625. PubMed ID: 35662507
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drug discovery and assay development in the ubiquitin-proteasome system.
    Berkers CR; Ovaa H
    Biochem Soc Trans; 2010 Feb; 38(Pt 1):14-20. PubMed ID: 20074028
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovering proteasomal deubiquitinating enzyme inhibitors for cancer therapy: lessons from rational design, nature and old drug reposition.
    Patel K; Ahmed ZS; Huang X; Yang Q; Ekinci E; Neslund-Dudas CM; Mitra B; Elnady FA; Ahn YH; Yang H; Liu J; Dou QP
    Future Med Chem; 2018 Sep; 10(17):2087-2108. PubMed ID: 30066579
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of proteasome in malignant diseases.
    Moran E; Nencioni A
    J BUON; 2007 Sep; 12 Suppl 1():S95-9. PubMed ID: 17935285
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel nickel complex works as a proteasomal deubiquitinase inhibitor for cancer therapy.
    Zhao C; Chen X; Zang D; Lan X; Liao S; Yang C; Zhang P; Wu J; Li X; Liu N; Liao Y; Huang H; Shi X; Jiang L; Liu X; He Z; Dou QP; Wang X; Liu J
    Oncogene; 2016 Nov; 35(45):5916-5927. PubMed ID: 27086925
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.